Please login to the form below

Not currently logged in
Email:
Password:

Dr P V Appaji appointed first director general of India’s Pharmexcil

Raghuveer Kini takes over executive director position at body to promote Indian pharmaceutical sector

The Pharmaceutical Export Promotion Council of India (Pharmexcil) has appointed former executive director Dr P V Appaji to the newly created position of director general.

The council, which aims to promote the Indian pharmaceutical sector to global markets, said as part of its internal review it had decided to create the new post to 'forgo the growing work pressure' on the executive director.

Dr Appaji's former role has been taken over by Raghuveer Kini, who had previously served as of additional executive director at Pharmexcil.

“Now, my job will be to focus more on policy matters. In the next one to two months we will organise a meeting and come out with a new frame work for our export activities,” said Dr Appaji.

He will also supervise the overall functioning of the council.

Specific events Dr Appaji will be involved in include the 15th South East Asia Healthcare & Pharma Show in Malaysia, where Pharmexcil will aim to India's role in manufacturing and exporting pharmaceutical products.

12th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics